Skip to content
Screener

Operating Income at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$336.6M+702%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$123.16M-30.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$60.81M-106%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
-$1.96M+61.2%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$193.4M+719%

Other financials

Income statement

See full
Revenue--100%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation

See full
Market cap$8.9B+770%
Enterprise value$8.43B+873%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0.0×
Current ratio15.7×+9.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001689548-26-000083
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development$69,416$63,006$147,403$123,812
General and administrative27,48813,06155,36126,983
Total operating expenses96,90476,067202,764150,795
Loss from operations(96,904)(76,067)(202,764)(150,795)
Other income:
Other income, net13,1844,94026,48310,372
Total other income13,1844,94026,48310,372
Net loss$(83,720)$(71,127)$(176,281)$(140,423)

Item 1. Financial Statements (Unaudited)

FAQ

What is Praxis Precision Medicines, Inc.'s operating income?
Praxis Precision Medicines, Inc. (PRAX) reported operating income of -$96.9M in Q2 2026.
How has Praxis Precision Medicines, Inc.'s operating income changed year-over-year?
Praxis Precision Medicines, Inc.'s operating income decreased by 27.4% year-over-year, from -$76.07M to -$96.9M.
What is the long-term trend for Praxis Precision Medicines, Inc.'s operating income?
Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s operating income has grown at a 18.2% compound annual growth rate (CAGR), from -$167.33M to -$326.2M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Praxis Precision Medicines, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude